Mesoblast Limited (NASDAQ:MESO) Given Average Recommendation of “Hold” by Analysts

Mesoblast Limited (NASDAQ:MESO) has been given an average recommendation of “Hold” by the six ratings firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $13.67.

MESO has been the topic of several recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Mesoblast in a report on Friday, January 12th. StockNews.com cut shares of Mesoblast from a “hold” rating to a “sell” rating in a report on Tuesday, April 2nd.

Mesoblast Stock Performance

Shares of MESO stock opened at $5.11 on Friday. Mesoblast has a 12-month low of $1.61 and a 12-month high of $10.24. The firm has a 50 day moving average price of $3.32 and a two-hundred day moving average price of $2.59.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Vident Investment Advisory LLC increased its stake in Mesoblast by 12.8% in the fourth quarter. Vident Investment Advisory LLC now owns 28,080 shares of the company’s stock valued at $82,000 after acquiring an additional 3,191 shares during the last quarter. Lazari Capital Management Inc. increased its stake in Mesoblast by 9.3% in the third quarter. Lazari Capital Management Inc. now owns 94,034 shares of the company’s stock valued at $116,000 after acquiring an additional 8,000 shares during the last quarter. EWA LLC bought a new position in Mesoblast in the first quarter valued at approximately $40,000. Envestnet Asset Management Inc. increased its stake in Mesoblast by 99.2% in the fourth quarter. Envestnet Asset Management Inc. now owns 26,008 shares of the company’s stock valued at $76,000 after acquiring an additional 12,954 shares during the last quarter. Finally, Wells Fargo & Company MN increased its stake in Mesoblast by 55.0% in the second quarter. Wells Fargo & Company MN now owns 52,813 shares of the company’s stock valued at $206,000 after acquiring an additional 18,747 shares during the last quarter. 1.43% of the stock is owned by institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.